D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

LuxIA, an AI algorithm co-developed by RetinAI US and non-profit organisation Fundación Ver Salud (FVS), has achieved CE-MDR ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

D Molecular Therapeutics (NASDAQ:FDMT) achieves FDA RMAT status for 4D-150 as a diabetic macular edema treatment, backed by ...

Complete A to Z disease and conditions health guide which provides information on a wide range of diseases and its symptoms, treatment, prevention and cure at thehealthsite.com ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes.

Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor ...